EMA allows emergency use of MSD's Covid-19 capsule treatment

MSD's capsule should be taken as early as possible after a Covid-19 diagnosis, within five days of symptoms beginning, the EMA instructs.


As Covid-19 cases soar in many places throughout Europe, the European Medicines Agency (EMA) has issued advice on Friday pertaining to the emergency use of MSD's Covid-19 capsule molnupiravir.

At the same time, the EMA announced that it was beginning a review of Pfizer's oral antiviral drug, which has received some interest recently.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs